

Literatur

(1) Tuteja S, Rader D. SLCO1B1 and statin therapy. Getting the GIST of pharmacogenetic testing, *Circ Genom Precis Med*. 2018;11/9:e002320. <https://doi.org/10.1161/CIRCGEN.118.002320>

(2) Pasanen M K, Neuvonen M, Neuvonen P J, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. *Pharmacogenetics and genomics*. 2006;16/12:873–879. <https://doi.org/10.1097/01.fpc.0000230416.82349.90>

(3) Search Collaborative Group. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy- a genomewide study. *The New England Journal of Medicine*. 2008;359:789-799.

(4) Niemi M, Pasanen M K, Neuvonen P J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. *Pharmacological reviews*. 2011;63/1:157–181. <https://doi.org/10.1124/pr.110.002857>

(5) Niemi M. Transporter pharmacogenetics and statin toxicity. *Clinical pharmacology and therapeutics*. 2010;87/1:130–133. <https://doi.org/10.1038/clpt.2009.197>